|Bid||37.24 x 1800|
|Ask||37.29 x 1000|
|Day's range||36.75 - 37.26|
|52-week range||26.45 - 39.84|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||24.21|
|Earnings date||26 Jan 2021 - 01 Feb 2021|
|Forward dividend & yield||1.52 (4.08%)|
|Ex-dividend date||05 Nov 2020|
|1y target est||41.78|
As COVID-19 hospitalizations surpass 90,000 for the first time, a record for the seventeenth day in a row, Dr. Andre Campbell, a trauma surgeon at Zuckerberg San Francisco General Hospital, warns the U.S. could be facing an “apocalypse” next month.
On Friday, the government wrote to the Medicines and Healthcare Products Regulatory Agency, asking it to review the Astrazeneca-Oxford University vaccine.
As the excitement over Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) vaccine announcement ebbs, some harsh realities have started to set in. The vaccine candidate -- while a marvelous feat of science -- has some hurdles to overcome if it's going to fulfill the promise of helping end the global pandemic. Let's look at a few issues the potential Pfizer vaccine will have to overcome to reward shareholders and save lives.